Media headlines about KalVista Pharmaceuticals (NASDAQ:KALV) have trended somewhat positive on Saturday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. KalVista Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 46.5719687677985 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Separately, ValuEngine upgraded KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 2nd.
Shares of KalVista Pharmaceuticals (KALV) traded up 11.30% on Friday, hitting $6.50. The stock had a trading volume of 54,672 shares. KalVista Pharmaceuticals has a 52-week low of $5.48 and a 52-week high of $10.65. The firm’s market cap is $63.13 million. The firm’s 50-day moving average price is $7.08 and its 200 day moving average price is $7.36.
KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, July 27th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter. KalVista Pharmaceuticals had a negative net margin of 5,863.31% and a negative return on equity of 63.41%. The company had revenue of $0.11 million during the quarter. On average, equities research analysts predict that KalVista Pharmaceuticals will post ($1.07) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact KalVista Pharmaceuticals (KALV) Share Price” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/26/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-kalvista-pharmaceuticals-kalv-share-price.html.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
